Sort
51,593 grants matching “hepatitis”
TREATMENT OF ADDICTIONS-BIOLOGICAL CORRELATES
$2,698,607Mary J Kreek · Rockefeller University · P60 · FY2007 · DA
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,696,586Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2014 · ES
KARABELO Clinical Trials Unit for NIAID Networks
$2,693,563Glenda E Gray · Wits Health Consortium (Pty), Ltd · UM1 · FY2014 · AI
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,684,642Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2018 · ES
NIH-Owned Chimpanzee Research Resource at the SNPRC
$2,681,884John L Vandeberg · Texas Biomedical Research Institute · U42 · FY2012 · OD
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,680,709Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2022 · AG
Chemoprophylaxis for HIV Prevention in Men
$2,680,398Robert M. Grant · J. David Gladstone Institutes · U01 · FY2007 · AI
Vanderbilt HIV Clinical Trials Unit (CTU)
$2,679,601David W Haas · Vanderbilt University Medical Center · UM1 · FY2022 · AI
SCORE Program at New Mexico State University, Las Cruces
$2,678,724Glenn D Kuehn · New Mexico State University Las Cruces · S06 · FY2006 · GM
ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE)
$2,678,459Devanand Sarkar · Virginia Commonwealth University · P01 · FY2024 · CA
Sirtuins and nuclear receptors in aging and age-associated diseases
$2,675,793Xiaoling Li · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations
$2,667,277Sandra Ann Springer · Yale University · U01 · FY2023 · DA
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations
$2,665,428Sandra Ann Springer · Yale University · U01 · FY2021 · DA
University of North Carolina Global HIV Prevention and Treatment Clinical Trials
$2,665,274Joseph J. Eron · Univ Of North Carolina Chapel Hill · UM1 · FY2015 · AI
Immune Pathophysiology of Aplastic Anemia and Immunosuppressive Treatments
$2,664,647Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2014 · HL
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers
$2,652,771Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2025 · DA
Washington Metro Women's Interagency HIV Study(WIHS)lll
$2,652,607Mary A Young · Georgetown University · U01 · FY2007 · AI
Durban International Clinical Trials Unit
$2,651,567Umesh G Lalloo · Ukzn Innovation · U01 · FY2010 · AI
Vanderbilt HIV Clinical Trials Unit (CTU)
$2,649,501David W Haas · Vanderbilt University Medical Center · UM1 · FY2024 · AI
Chicago Consortium Women's Interagency HIV Study lll
$2,649,275Mardge H Cohen · Hektoen Institute For Medical Research · U01 · FY2006 · AI
The Asia-Pacific HIV Research Collaboration
$2,648,236David A Cooper · Foundation For Aids Research · U01 · FY2012 · AI
Optimization of Fetal Hemoglobin Production to Prevent or Reverse Organ Damage and Improve Survival in Patients with Sickle Cell Disease
$2,646,917Courtney Fitzhugh · National Heart, Lung, And Blood Institute · ZIA · FY2016 · HL
ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE)
$2,646,688Devanand Sarkar · Virginia Commonwealth University · P01 · FY2025 · CA
Childhood Liver Disease Research Network Data Coordinating Center
$2,644,921John C Magee · University Of Michigan At Ann Arbor · U01 · FY2019 · DK
Stroke with Transfusions Changing to Hydroxyurea
$2,644,329St. Jude Children'S Research Hospital · U01 · FY2005 · HL